Featured

Status

Health Topics

Any Category
Diseases
Hemic and Lymphatic Diseases
Clear Filters

Search Clinical Trials

65 Results
Terminated
Eosinophilic Esophagitis Clinical Therapy Comparison Trial
This study is a open label, randomized, prospective clinical trial comparing the efficacy of a topical steroid preparation to an antigen (food) elimination diet. A total of 40 participants will …
Baylor Role: Lead Sponsor
Completed
A Phase II Trial of Regadenoson in Sickle Cell Anemia
If you are willing to participate in this research study you will be asked to undergo some screening tests and procedures to confirm your eligibility. Many of these tests and …
Baylor Role: Collaborator
Active, Not Recruiting
Morphological Markers of Gastroesophageal Reflux Disease (GERD)
This will be a prospective case control study. Children between the ages of 8 and 18 with suspected gastroesophageal reflux disease (GERD) or eosinophilic esophagitis (EoE) based on symptom criteria …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC is part of a spectrum …
Baylor Role: Collaborator
Active, Not Recruiting
Administration of Donor T Cells With the Caspase-9 Suicide Gene
If the patient is doing well after the stem cell transplant, and does not have severe GvHD, s/he will be eligible to receive the special "iCasp9" T cells from Day …
Baylor Role: Lead Sponsor
Terminated
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
Despite the clear results of the STOP and the follow-up STOP II trials, the use of chronic erythrocyte transfusions for primary stroke prevention in children with Sickle Cell Anemia (SCA) …
Baylor Role: Collaborator
Completed
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
The following will be given as the conditioning regimen for the transplant: BUSULFAN: Busulfan (intravenous BUSULFEX) dosing will be as follows: patients <12 kg: 1.1 mg/kg/dose IV every 6 hours …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role: Collaborator
Recruiting
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
To prepare the lymphoma, MM or CLL specific T cells investigators will take 240 ml (up to 16 tablespoonfuls)of blood from the patient. This would be drawn as 2 (two) …
Baylor Role: Lead Sponsor
Active, Not Recruiting
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Because the patient will receive cells with a new gene in them, they will be followed for a total of 15 years to see if there are any long-term side …
Baylor Role: Lead Sponsor